



## Proton Therapy at Institute Curie expands research capabilities with a new experimental beam line

### New agreement signed with IBA for installation and ongoing research

**Paris, France, July 1, 2016** - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, and the Institute Curie announce today the signature of an agreement for the manufacturing, delivery, installation and maintenance of a new research beam line. This line will be connected to the existing beam transport line. This agreement also includes future research projects to be performed jointly by the two organizations over the coming ten years.

The line includes a Nozzle capable of delivering Pencil Beam Scanning, the most advanced delivery mode of proton therapy. The installation will be done without impacting the current clinical activities in the treatment rooms and is scheduled to be operational in 2018.

**Olivier Legrain**, CEO of IBA commented: "IBA is delighted to deliver this additional beam line to the proton therapy center at Orsay. There is a long standing partnership between the prestigious Institute Curie and IBA. This agreement opens new avenues for joint research that will improve the quality of the proton treatment in Paris and all over the world. This agreement illustrates IBA capability to upgrade existing PT Centers equipped with IBA technology, keeping them at the forefront of research and advanced treatments in the fight against cancer."

**Dr Alain Fourquet**, Head of the Radiotherapy Department at Institute Curie said: "This new research line and possibilities it opens for our researchers is important for Institute Curie. It reflects our commitment to leading proton therapy research and treatment. We are happy to be working with IBA, because of their ongoing commitment to innovation and support of users."

### About Institute Curie

**Institute Curie** is a private foundation granted charitable status, which combines one of the largest oncology research centers in Europe and a state-of-the-art hospital group. This hospital structure has pioneered many treatments. It is a center of excellence for the treatment of breast cancer, pediatric tumors and ocular tumors as well as treating all types of cancer, and it disseminates medical and scientific innovations in France and abroad.

Founded in 1909 on a model devised by Marie Curie, twice winner of the Nobel Prize, and still at the cutting edge: "from fundamental research to innovative treatments", Institute Curie has 3,300 researchers, physicians, clinicians, technicians and administrative staff devoted to giving patients their very best, every day.

For more information: [www.curie.fr/en](http://www.curie.fr/en)



## About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single-room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1300 people worldwide, IBA has installed systems across the world, from Europe, the US and Asia. IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) More information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com).

## **IBA**

### **Jana Kulhankova**

Marketing Associate Proton Therapy

+32 10 203652

[jana.kulhankova@iba-group.com](mailto:jana.kulhankova@iba-group.com)

### **Thomas Ralet**

Vice-President Corporate Communication

+32 10 47 58 90

[communication@iba-group.com](mailto:communication@iba-group.com)